The Neurofibromatosis Therapeutic Acceleration Program (NTAP) (www.n-tap.org) is a philanthropic research entity based at Johns Hopkins University School of Medicine dedicated to the discovery of therapeutics for the peripheral nerve tumors that afflict people with Neurofibromatosis Type 1 (NF1).

We are excited to announce a Requests for Applications for up to 15 funded projects. Funded projects are anticipated to last from 12-36 months and require $300,000-$1,000,000 per project. Investigators can request funding or duration above or below this range with appropriate justification.

Areas of special interest include:
1. Investigate the processes underlying the stages of cNF initiation, progression, maintenance and senescence.
2. Identify and validate therapeutic candidates across the various stages and expressions of cNF.
3. Identify or validate non-invasive approaches in humans and preclinical systems for detection and assessment of growth or response of cNF.
4. Define or validate key variables and endpoints for cNF clinical trials.
5. Develop the infrastructure for patient-driven engagement programs to enable registries and rapid enrollment into clinical trials for cNF.

Learn more about the opportunity HERE

Investigators can be from academia, government, or private sector. International candidates, multidisciplinary teams and investigators new to NF1 are welcomed.

The letter of intent is due 8/5/2022
The full application is due 9/2/2022 via ProposalCentral.